Compass Therapeutics (NASDAQ:CMPX) Research Coverage Started at Craig Hallum

Craig Hallum initiated coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a research note published on Friday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $15.00 price objective on the stock.

CMPX has been the subject of a number of other research reports. D. Boral Capital reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, January 6th. Citizens Jmp began coverage on Compass Therapeutics in a research note on Wednesday, December 3rd. They issued a “market outperform” rating and a $10.00 price target on the stock. Wall Street Zen cut Compass Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, February 8th. JMP Securities set a $10.00 price objective on shares of Compass Therapeutics in a report on Wednesday, December 3rd. Finally, Citigroup assumed coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $13.00.

Compass Therapeutics Stock Performance

Shares of NASDAQ CMPX opened at $6.28 on Friday. Compass Therapeutics has a 1 year low of $1.33 and a 1 year high of $6.88. The firm’s 50 day moving average price is $5.67 and its 200 day moving average price is $4.51. The firm has a market cap of $1.12 billion, a P/E ratio of -13.96 and a beta of 1.46.

Institutional Investors Weigh In On Compass Therapeutics

Several institutional investors have recently bought and sold shares of the business. Suvretta Capital Management LLC increased its position in shares of Compass Therapeutics by 97.2% in the third quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock worth $49,354,000 after acquiring an additional 6,951,666 shares in the last quarter. Vivo Capital LLC boosted its position in Compass Therapeutics by 57.9% during the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock worth $33,409,000 after purchasing an additional 3,502,000 shares during the period. Balyasny Asset Management L.P. acquired a new stake in Compass Therapeutics in the 3rd quarter valued at $9,892,000. Millennium Management LLC raised its position in Compass Therapeutics by 280.4% in the third quarter. Millennium Management LLC now owns 3,237,572 shares of the company’s stock valued at $11,332,000 after purchasing an additional 2,386,367 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Compass Therapeutics by 45.6% during the third quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock worth $24,720,000 after purchasing an additional 2,212,794 shares in the last quarter. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.